US Bancorp
RXRX icon

US Bancorp’s Recursion Pharmaceuticals RXRX Stock Holding History

US Bancorp’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52K Sell
16,940
-11,544
-41% -$44.6K ﹤0.01% 2692
2025
Q4 		$117K Buy
28,484
+5,985
+27% +$29.6K ﹤0.01% 2287
2025
Q3 		$110K Buy
22,499
+326
+1% +$1.71K ﹤0.01% 2309
2025
Q2 		$112K Buy
22,173
+20,302
+1,085% +$99.7K ﹤0.01% 2369
2025
Q1 		$9.9K Buy
1,871
+163
+10% +$1.19K ﹤0.01% 3437
2024
Q4 		$11.5K Sell
1,708
-455
-21% -$3.06K ﹤0.01% 3353
2024
Q3 		$14.3K Buy
2,163
+1,453
+205% +$10.4K ﹤0.01% 3236
2024
Q2 		$5.33K Buy
710
+45
+7% +$392 ﹤0.01% 3489
2024
Q1 		$6.63K Buy
+665
New +$7.41K ﹤0.01% 3457
2023
Q3 		– Sell
-115
Closed -$859 – 4096
2023
Q2 		$859 Buy
+115
New +$805 ﹤0.01% 3824
2022
Q4 		– Sell
-16,200
Closed -$172K – 4267
2022
Q3 		$172K Hold
16,200
– – ﹤0.01% 1928
2022
Q2 		$132K Buy
+16,200
New +$108K ﹤0.01% 2088

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

US Bancorp's RXRX Position: Q1 2026 in Review

US Bancorp reduced its Recursion Pharmaceuticals (RXRX) stake by 41% in Q1 2026, selling an estimated $44.6K and leaving 16,940 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

US Bancorp first reported a position in RXRX in Q2 2022 and has held it in 12 quarters since. The position peaked at $172K in Q3 2022. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • US Bancorp held 16,940 shares of Recursion Pharmaceuticals worth $52K as of Q1 2026.
  • US Bancorp sold 11,544 Recursion Pharmaceuticals shares in Q1 2026, an estimated $44.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2692 holding.
  • US Bancorp first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
  • US Bancorp's Recursion Pharmaceuticals position peaked at $172K in Q3 2022.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.